Targeting the TGF-β signaling pathway to inactivate CAFs and breach the “physical barrier” might be a promising strategy to overcome the exclusion of CTLs and improve the therapeutic efficacy of cancer immunotherapy11. This evidence concerns the gene TGFB1 and cancer.